Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Immutep ( (IMMP) ) is now available.
Immutep Limited has announced significant progress in its clinical trials and research activities for the quarter ending June 30, 2025. The company is advancing its TACTI-004 Phase III trial for non-small cell lung cancer, with patient recruitment expanding across 78 sites in 23 countries. The INSIGHT-003 trial showed promising results with a high response rate in lung cancer patients, while the EFTISARC-NEO trial in soft tissue sarcoma met its primary endpoint. Additionally, the company reported positive initial data from its IMP761 Phase I trial for autoimmune diseases, highlighting its potential efficacy. Immutep maintains a strong cash position, supporting its operations through the end of 2026.
The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall score reflects the high-risk, high-reward nature of an early-stage biotech company. Strong financial stability from a solid balance sheet is offset by profitability challenges and negative cash flows. Technical analysis suggests some positive momentum, but the valuation remains a concern due to unprofitability.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is a clinical-stage biotechnology company based in Sydney, Australia, focusing on the development of novel LAG-3 immunotherapies for cancer and autoimmune diseases.
Average Trading Volume: 292,790
Technical Sentiment Signal: Sell
Current Market Cap: $255.7M
See more insights into IMMP stock on TipRanks’ Stock Analysis page.